Patients with histologically proven malignant glioma will be eligible for this protocol Malignant glioma include glioblastoma multiforme GBM anaplastic astrocytoma AA anaplastic oligodendroglioma AO anaplastic mixed oligoastrocytoma AMO or malignant glioma NOS not otherwise specified Additionally patients with primitive neuroectodermal tumors PNETs of the central nervous system progressive low-grade gliomas and radiographically diagnosed brain stem gliomas refractory to standard treatment will be eligible 